144 results about "Type antigen" patented technology

The invention provides a method for preserving the activity of a human cell membrane blood group antigen, which comprises the steps of: preparing an erythrocyte membrane blood group antigen extract, and then coating the prepared erythrocyte membrane blood group antigen on a solid microsphere so as to replace a fresh erythrocyte to be used for detecting a blood group antibody in a sample.

The present invention includes novel influenza antigenic formulations and vaccines that comprise influenza M2 peptide and VLPs comprising influenza M2 protein. The invention also includes methods of making and administering the novel antigenic formulation and vaccine. The invention also include methods of inducing immunity to ameliorate and/or prevent influenza infections in a subject.

The invention discloses a chemical synthesis method of plesiomonas shigelloides O51 serotype O-antigen oligosaccharide, and belongs to the field of chemistry. According to the chemical synthesis method, D-glucose with rich resources is adopted, L-fucose and D-glucosamine and the like serve as raw materials to prepare three kinds of glycosylation building blocks, a synthetic route composed of eleven reaction modules is designed, and the preparation of a target oligosaccharide chain is completed successfully through the optimization of a protecting group and the optimization of the introductiontiming of a modified group. Raw materials of the prepared oligosaccharide chain is cheap and obtained easily, the preparation method is simple and repeated easily, and the oligosaccharide chain has agood application prospect in the development of novel drugs and vaccines of plesiomonas shigelloides and the like.

The invention provides a vaccine composition, a preparation method and an application thereof. The vaccine composition includes: an immune dose of porcine circovirus 2-type antigen, an immune dose of porcine Japanese encephalitis virus antigen, an immune dose of porcine parvovirus antigen and an adjuvant. The vaccine composition can effectively prevent and cure postweaning piglet multisystemic syndrome and sow reproduction dysfunctional diseases which are caused by 2-type porcine circovirus, porcine Japanese encephalitis virus and porcine parvovirus. An immune effect of the vaccine composition is better than that of a single vaccine. The vaccine composition is little in side effects, is high in valence of a serum antibody, has a long immune period, can save time and labor intensity, has a small stress response to a pig, can simplify immunity processes and can reduce production cost and prevention cost.

The invention discloses an artificial antigen submitting cell and preparing method, which comprises the following steps: choosing human chronic granular leukocyte leukemia bacterial strain K562 cell as carrier; transfer-dying and expressing eucaryon expressing carrier of CD32a; expressing CD32 molecular on the surface of K562 cell stably through G418 screening and flowed cell sorting device sorting; forming K32 cell; producing eucaryon expressing carrier of double expressing CD86 and 4-1BBL co-simulating signal; proceeding homomycin screen and sort with flowed cell device for the K32 cell; getting stable expression K32 cell of CD86 and 4-1BBL molecule; getting the end product. This invention possesses low cost and good repeatability, which can inhibit die effectively.

The invention relates to the field of biomedicine, and specifically relates to an enterovirus 71 antigen detection test strip (colloidal gold method) and a preparation method and application thereof. Enterovirus 71 can cause hand-foot-and-mouth disease, which has largegeneration proportion of severe infections (viral encephalitis, meningomyelitis virus and pulmonary edema), and a high death rate reaching 10%-25%. The test strip of the invention is used for rapid diagnosis of EV(enterovirus)71 infection. A virus separation and an RT-PCR (reverse transcription-polymerase chain reaction) are methods first used for EV71 antigen detection, but are not suitable for primary clinic usage due to defects of difficult operation and high costs, etc. The invention overcomes the above insufficiencies and provides a reagent, which is highly demanded in clinic detection, simply operated, suitable for various medical disease control sections, and capable of detecting EV71 antigens in human oropharyngeal swabs, bubble liquid, serum or excrement, and also provides the preparation method and application thereof. A technical scheme is as follows: a specimen is dropped on a sample pad, and the EV71 antigen wherein combines with a gold-labeled EV71 polyclonal antibody in a gold-labeled pad and migrates along a chromatography membrane. A detected line captures colloidal gold particles to form a red line visible to naked eyes, so as to realize detection of the EV71 antigen.

The invention relates to the field of gene engineering, and particularly relates to an anti-VEGFR-1 (Vascular Endothelial Growth Factor Receptor-1) mosaic type antigen receptor and lymphocyte capable of expressing the antigen receptor, and aims at providing a new and effective choice for the technical field of antitumor. The technical scheme for solving the technical problems is as follows: a single-chain antibody ScFv is provided, the single-chain antibody can recognize VEGFR-1, the single-chain antibody is prepared into the mosaic type antigen receptor which has a structure of (ScFv-V)-(IgG1-Fc)-(CD4-TM)-(CD3-z), the encoding gene of the antigen receptor is transformed into a plasmid vector, and the plasmid vector is transfected to lymphocyte, so that the lymphocyte has antitumor action, thereby providing the new and effective choice for the field.

The invention provides an avian adenovirus fiber protein subunit vaccine. A new-type antigen fiber protein of an avian adenovirus is used, after a sequence is optimized, the fiber protein acquires soluble expression in escherichia coli, and an expression product is used for preparing the subunit vaccine, wherein an amino acid sequence of the avian adenovirus fiber antigen protein is SEQ ID NO: 4,and a nucleotide sequence of an encoding gene thereof is SEQ ID NO: 3. The subunit vaccine prepared by the avian adenovirus fiber protein has the characteristics of high antigen stability, high purity, strong specificity, no generation of other uncorrelated antibodies, and convenient and accurate detection method. A firm foundation is established for industrially producing the avian adenovirus subunit vaccine and diagnostic reagent.

The invention belongs to the technical field of biomedicine and bioinstrumentation, in particular to an epitope (Bcellepitope) minimum motif peptide of human papilloma virus (HPV) type 58 L1 structural protein and application thereof. The invention provides 16 amino acid sequences containing minimum motif peptide (including 8 peptide sequence capable of cutting off expression of carrier protein such as GST188), and the amino acid sequences can be taken as antigen for independently or combinedly specific detection of blood serum of HPV type 58 virus infection patient and can be used for developing preventive HPV type 58 multi-epitope peptide vaccine capable of simultaneously inducing humoral immunity. The amino acid sequences of HPV type 58 L1 epitope minimum motif peptide and short peptide are shown as SEQIDNo.1-SEQIDNo.32.

The invention relates to a porcine circovirus II type-porcine pseudorabies double-combination vaccine which is characterized by including at least one porcine circovirus II type antigen and at least one porcine pseudorabies virus antigen. The invention also relates to two preparation methods of the double-combination vaccine. One method comprises the steps: inactivating the porcine circovirus II type to obtain a porcine circovirus II type inactivated vaccine; and mixing the porcine pseudorabies virus antigen with a freeze-drying protective agent to obtain a porcine pseudorabies freeze-drying living vaccine, and then dissolving the porcine pseudorabies freeze-drying living vaccine with the inactivated vaccine as a diluent to obtain the porcine circovirus II type-porcine pseudorabies double-combination vaccine composition. The other method comprises the steps: mixing the porcine circovirus II type antigen with the porcine pseudorabies virus antigen in proportion, and then mixing with the freeze-drying protective agent to obtain the double-combination freeze-drying vaccine. With use of the double-combination vaccine, the cold chain operating cost can be greatly reduced; and the combination vaccine has a synergistic role in the immune effect on the porcine pseudorabies virus antigen, and does not affect the immune effect of the porcine circovirus antigen.

The present invention relates to a new type antigen detection method. Said method utilizes the direct combination of antibody Fc fragment specific oligonucleotide ligand and antibody, and converts the antibody signal into nucleic acid signal, then utilizes PCR amplification technique to detect antigen. The utilization of said method can form the detection kit or develop practical protein ship or other biological chip for detecting other various antigens.

The invention relates to analysis of an acinetobacter baumannii (Ab) Sv4-serotype O antigen by using an MGB probe-based real-time fluorescent TaZMan polymerase chain reaction rapid detection system. Aspecific gene, Wzy, in an acinetobacter baumannii O antigen gene cluster is adopted as a target gene so as to establish a primer and MGB probe for typing the acinetobacter baumannii O antigen, and areliable route is provided for typing of the O antigen of acinetobacter baumannii in blood, urine, pus and a respiratory tract. When the MGB probe is applied to detection of acinetobacter baumannii inthe blood, urine, pus and respiratory tract, and O-antigen typing of acinetobacter baumannii is performed, high sensitivity, high specificity, rapid detection and other advantages are achieved.

The invention discloses a ready-to-use rapid enzyme immune tissue chemical reagent kit for detecting SCML2. The ready-to-use rapid enzyme immune tissue chemical reagent kit comprises a kit body, the kit body is provided with a 3% H2O2 deionized water container, a powder type antigen repair solution container and a powder type phosphate buffer solution container, and the kit body is further provided with a monoclonal mouse anti-human SCML2 antibody container, a polymer enhancer container, an HRP enzyme-labeled mouse IgG polymer container and a diaminobenzidine container; a reagent in the reagent kit comprises the components of 3% H2O2, powder type antigen repair solutions, powder type phosphate buffer solutions, monoclonal mouse anti-human SCML2 antibodies, polymer enhancers, HRP enzyme-labeled mouse IgG polymers and diaminobenzidine. The ready-to-use rapid enzyme immune tissue chemical reagent kit for detecting SCML2 has the advantages that the detection operation process is greatly simplified, and it can be guaranteed that the detection result has good quality control; the ready-to-use rapid enzyme immune tissue chemical reagent kit for detecting SCML2 further has the advantages of being simple, fast to use, sensitive, universal, good in reproducibility and low in cost.

A PCV2 antigen subtype identification test paper card is applicable to pig PCV2 subtype identification. A reaction reagent carrier absorption layer comprises a fiber layer, a gold-labeled fiber layer, a cellulose membrane layer and a water absorbent material layer; wherein the gold-labeled fiber layer is gold-labeled glass cotton of an anti-capsid protein monoclonal antibody which absorbs a colloidal gold marker and can identify PCV common antigen epitope, detection blots T1, T2 and T3 and a control blot C are printed on the cellulose membrane layer; the detection blot T1 is the blot which is printedby anti-capsid protein monoclonal antibody solution and used for identifying <1767>PCV2 subtype specific antigen epitope, the detection blot T2 is the blot which is printed by the anti-capsid proteinmonoclonal antibody solution and used for identifying <1766>PCV2 and <1767>PCV2 common antigen epitope, the detection blot T3 is the blot which is printed by the anti-capsid protein monoclonal antibody solution and used for identifying PCV2 common antigen epitope, and the control blot C is the blot which is printed by anti-mouse IgG polyclonal antibody solution. The test paper card has strong specificity, high sensitivity, intuitive detection result as well as easy popularization and application.

The invention relates to a composition containing a human papilloma virus (HPV) plasmodium and an immunopotentiator and being used for preventing or treating cervical cancer. The composition is characterized in that fusion protein is used for treating tumors caused by HPV through inducing HPV 16 and 18 type antigen-specific immune response, wherein the fusion protein comprises fusion polypeptide which is recombined to enable the three dimensional structures of HPV 16 and 18 type antigens E6 and E7 to deform; signal peptide which is used for secreting the fusion polypeptide; immunological enhancement peptide.

The invention belongs to the field of immunobiology, relates to immunogenic polypeptide for an enterovirus 71 type VP1 antigen as well as a preparation method and application of immunogenic polypeptide, in particular to immunogenic polypeptide for the enterovirus 71 type VP1 antigen, which has an amino acid sequence shown in any of sequence tables SEQ ID No.1-SEQ ID No.5 or has an amino acid sequence which has the same function and formed by replacing, deleting or adding one or more amino acids. The invention further relates to the preparation method of immunogenic polypeptide and application of immunogenic polypeptide to preparation of diagnostic reagents for EV71 viruses. The immunogenic polypeptide has good antigenicity and immunogenicity and provides a research foundation for development of diagnostic reagents and research on vaccines of EV71 at an early stage.

The invention belongs to the field of biological medicines, and particularly relates to an immunochromatography detection kit for a simple herpes virus II type IgM antibody. The kit is formed by assembling a reagent strip and a plastic card, wherein the reagent strip comprises a base plate; a reaction membrane with a detection line and a quality control line is adhered to the base plate; a colloidal gold pad and a sample pad are stacked and adhered to one end, which is close to the detection line, of the reaction membrane in sequence; an absorption pad is stacked and adhered to one end, which is close to the quality control line, of the reaction membrane; the detection line is coated with a simple herpes virus II type antigen; the quality control line is coated with a goat anti-mouse IgG antibody; and the colloidal gold pad is coated with a colloidal gold labeled mouse anti-human IgM monoclonal antibody. The kit disclosed by the invention can obviously reduce the influence of environmental factors (such as low temperature and high temperature) on a detection process and a detection result, and guarantee the sensitivity, the accuracy and the stability of the detection result.

The invention relates to the technical field of molecular biology and immunology and particularly relates to an enterovirus 71 type epitope, an antibody, application and a vaccine thereof. The epitope of the EV71 virus is located on a coat protein VP3 of the EV71 virus and is capable of specifically identifying the EV71 virus; besides, the epitope is presented through a PP carrier to cause a high neutralizing titer, and the serum after immunity is capable of effectively protecting the young rat from EV71 virus infection. The neutrality detection result of the polyclone on each EV71 subtype pseudovirus shows that the polyclonal antibody provided by the invention has high and broad-spectrum neutralizing titer. In addition, the passive protection and the maternal vertical protection experiments prove that the polyclonal antibody provided by the invention can completely protect the young rat from EV71virus infection.

The invention discloses a multivalent vaccine for bacillary dysentery, comprising the univalent conjugate of shigella different serological type antigen O-specific amylase conjugated carrier protein. The invention is characterized in that the multivalent vaccine is bivalent vaccine or more than bivalent till to forty-seven valence vaccine which are formed by at least two or more than two O-specific amylase univalent conjugates. After the shigella different serological type conjugates are mutually blended, the conjugates do not have physical change or chemic change and do not influence respective immunogenicity. The invention lays the foundation for developing vaccines for covering more shigella serological type multivalent conjugates and preventing more people from being attacked by the bacterial.